


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:48:47Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406060" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406060</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Network Open</journal-title></journal-title-group><issn pub-type="epub">2574-3805</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406060</article-id><article-id pub-id-type="pmcid-ver">PMC12406060.1</article-id><article-id pub-id-type="pmcaid">12406060</article-id><article-id pub-id-type="pmcaiid">12406060</article-id><article-id pub-id-type="pmid">40892411</article-id><article-id pub-id-type="doi">10.1001/jamanetworkopen.2025.29762</article-id><article-id pub-id-type="publisher-id">zoi250840</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="subject-area"><subject>Diabetes and Endocrinology</subject></subj-group></article-categories><title-group><article-title>Mobile App&#8211;Based Intervention and Cardiovascular Risk Factors in Patients With Uncontrolled Type 2 Diabetes</article-title><subtitle>A Randomized Clinical Trial</subtitle><alt-title alt-title-type="headline">Mobile App Intervention and Cardiovascular Risk Factors in Type 2 Diabetes</alt-title><alt-title alt-title-type="running-head">Mobile App Intervention and Cardiovascular Risk Factors in Type 2 Diabetes</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="PZ">Pei-Zhen</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="D">Dan</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="CQ">Chang-Qin</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="zoi250840aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="N">Ning</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="JF">Jian-Fang</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lei</surname><given-names initials="XZ">Xu-Zhen</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="LJ">Lin-Jie</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="YT">Ya-Ting</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="X">Xu</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="JF">Jun-Feng</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Du</surname><given-names initials="CM">Chun-Min</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="K">Kai</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mo</surname><given-names initials="W">Wei</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="JY">Jia-Yang</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="CSH">Chen-Si-Han</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="BY">Bing-Yan</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wei</surname><given-names initials="XY">Xue-Yun</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="DY">De-Ying</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="JL">Jun-Lin</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="Y">Yan</given-names></name><degrees>MS</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xue</surname><given-names initials="YM">Yao-Ming</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zeng</surname><given-names initials="YM">Yan-Mei</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="SQ">Shi-Qun</given-names></name><degrees>MD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ma</surname><given-names initials="ZM">Zhi-Min</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="zoi250840aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="HJ">Hui-Jie</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="zoi250840aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi250840aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="zoi250840aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib></contrib-group><aff id="zoi250840aff1"><label>1</label>Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China</aff><aff id="zoi250840aff2"><label>2</label>Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China</aff><aff id="zoi250840aff3"><label>3</label>Department of Endocrinology, Fudan University Zhongshan Hospital Xiamen Branch, Xiamen, China</aff><aff id="zoi250840aff4"><label>4</label>Department of Endocrinology &amp; Metabolism, Guangdong Second Traditional Chinese Medicine Hospital, Guangzhou, China</aff><aff id="zoi250840aff5"><label>5</label>Department of Endocrinology, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, China</aff><aff id="zoi250840aff6"><label>6</label>Guangdong Provincial Key Laboratory of Shock and Microcirculation, Guangzhou, China</aff><aff id="zoi250840aff7"><label>7</label>State Key Laboratory of Organ Failure Research, Guangzhou, China</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> June 16, 2025.</p><p content-type="published-online"><bold>Published:</bold> September 2, 2025. doi:<uri content-type="doi">10.1001/jamanetworkopen.2025.29762</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#169; 2025 Zhang PZ et al. <italic toggle="yes">JAMA Network Open</italic>.</p><corresp id="zoi250840cor1"><bold>Corresponding Authors:</bold> Hui-Jie Zhang, MD, PhD, Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, 1838 N Guangzhou Ave, Guangdong 510515, China (<email xlink:href="huijiezhang2005@126.com">huijiezhang2005@126.com</email>); Zhi-Min Ma, MD, PhD, Department of Endocrinology, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 1 Lijiang Rd, Suzhou New District, Jiangsu 215153, China (<email xlink:href="mazhimin01@sina.com">mazhimin01@sina.com</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr H.-J. Zhang had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs P. Z. Zhang, Guo, and C. Q. Liu contributed equally to this work.</p><p><italic toggle="yes">Concept and design</italic>: P. Zhang, Guo, C. Liu, H. Zhang.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> All authors.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> P. Zhang, Guo, Lei, Y. Liu, Y. Huang, H. Zhang.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content</italic>: C. Liu, Chen, J. Liu, Yang, Li, Junfeng Huang, Du, Wang, Mo, Lin, C. Huang, Xu, Wei, D. Liu, Junlin Huang, Xue, Zeng, S. Liu, Ma, H. Zhang.</p><p><italic toggle="yes">Statistical analysis:</italic> P. Zhang, Guo, Lei, Y. Liu, Du, Xu, Wei, D. Liu, Ma, H. Zhang.</p><p><italic toggle="yes">Obtained funding:</italic> P. Zhang, Guo, H. Zhang.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> C. Liu, Chen, Lei, Li, Mo, Y. Huang, Xue, Zeng, H. Zhang.</p><p><italic toggle="yes">Supervision:</italic> C. Liu, J. Liu, Lei, Junlin Huang, Y. Huang, S. Liu, H. Zhang.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> None reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This study was supported by grant 2023ZD0508300 from the Noncommunicable Chronic Diseases-National Science and Technology Major Project, grants 81970736 and 82400986 from the National Natural Science Foundation of China, award 82325011 from the National Science Fund for Distinguished Young Scholars, grant U22A20288 from the Joint Funds of the National Natural Science Foundation of China, grants LC2019ZD010 and 2019CR022 from the Key-Area Clinical Research Program of Southern Medical University, grant SL2024B03J00202 from the Guangzhou Science and Technology Plan Project, and award 2023B044 from the Dean&#8217;s Fund of Nanfang Hospital, Southern Medical University.</p><p><bold>Role of the Funder/Sponsor:</bold> The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI250840-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p><p><bold>Additional Contributions:</bold> The authors thank the clinical staff members and participants at all 5 clinic centers for their support throughout the study.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2025-09-02T10:00"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>8</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496127</issue-id><elocation-id>e2529762</elocation-id><history><date date-type="received"><day>15</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright 2025 Zhang PZ et al. <italic toggle="yes">JAMA Network Open</italic>.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="jamanetwopen-e2529762.pdf"/><self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2529762.pdf">jamanetwopen-e2529762.pdf</self-uri><self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.29762"/><related-article related-article-type="commentary" xml:lang="en" journal-id="JAMA Netw Open" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="40892416"><article-title>Modest Gains for Text Message Intervention in Type 2 Diabetes.</article-title><volume>8</volume><issue>9</issue><date><day>2</day><month>9</month><year>2025</year></date><fpage>e2529772</fpage><lpage>e2529772</lpage><source>JAMA Netw Open</source><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2025.29772</pub-id><pub-id pub-id-type="pmid">40892416</pub-id></related-article><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-zoi250840-1"><title>Question</title><p>Can a mobile message&#8211;based intervention improve cardiovascular risk factors among patients with uncontrolled type 2 diabetes?</p></sec><sec id="ab-zoi250840-2"><title>Findings</title><p>In this 12-month randomized clinical trial of 819 adults with uncontrolled type 2 diabetes comorbid with cardiovascular disease risk factors, when compared with usual care, adults receiving the message-based intervention had significant improvements in hemoglobin A<sub>1c</sub> levels and systolic blood pressure.</p></sec><sec id="ab-zoi250840-3"><title>Meaning</title><p>These findings suggest that mobile message&#8211;based strategies for improving glycemic control and cardiovascular disease risk factors should be considered for adults with type 2 diabetes.</p></sec></abstract><abstract abstract-type="teaser" specific-use="electronic"><p>This randomized clinical trial compares the effectiveness across 12 months of usual care with a mobile message&#8211;based intervention designed to remind, encourage, and motivate adults with type 2 diabetes and cardiovascular risk factors to participate in behaviors needed for improving glycemic control and risk factor management.</p></abstract><abstract><sec id="ab-zoi250840-4"><title>Importance</title><p>Controlling modifiable cardiovascular risk factors is important but underused for patients with type 2 diabetes (T2D). Mobile message&#8211;based intervention strategies could address this gap but lack evidence of benefit on multiple risk factors.</p></sec><sec id="ab-zoi250840-5"><title>Objective</title><p>To evaluate the effectiveness of a mobile message&#8211;based intervention in controlling cardiovascular risk factors in patients with T2D.</p></sec><sec id="ab-zoi250840-6"><title>Design, Setting, and Participants</title><p>In this randomized clinical trial, adults with uncontrolled T2D comorbid with cardiovascular disease (CVD) risk factors were recruited from 5 clinical centers in China. Data were collected from November 2018 to March 2022 and analyzed from January to June 2023.</p></sec><sec id="ab-zoi250840-7"><title>Intervention</title><p>Participants were randomized to receive either usual care or a mobile message&#8211;based intervention of 6 text messages per week from different modules designed to remind, encourage, and motivate them to participate in the behaviors needed for improving glycemic control and CVD risk factor management for 12 months.</p></sec><sec id="ab-zoi250840-8"><title>Main Outcomes and Measures</title><p>The primary outcome included mean changes in hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>), low-density lipoprotein cholesterol (LDL-C), and systolic blood pressure (SBP) levels across 12 months. The secondary outcomes included the percentage of participants with controlled HbA<sub>1c</sub> at 12 months. Data were analyzed using the intention-to-treat principle.</p></sec><sec id="ab-zoi250840-9"><title>Results</title><p>A total of 819 participants (552 men [67.4%]; mean [SD] age, 50.1 [11.9] years; mean [SD] HbA<sub>1c</sub> level, 10.2% [2.1%]) were enrolled, of whom 410 were randomized to the intervention group and 409 to the control group. During the 12-month intervention, significant reductions in the mobile message&#8211;based intervention group were observed for HbA<sub>1c </sub>levels by &#8722;2.8% (95% CI, &#8722;2.9% to &#8722;2.6%), LDL-C by &#8722;11.1 mg/dL (95% CI, &#8722;14.7 to &#8722;7.4 mg/dL), and SBP by &#8722;2.5 mm Hg (95% CI, &#8722;3.9 to &#8722;1.2 mm Hg), and in the usual care group, by &#8722;2.5% (95% CI, &#8722;2.7% to &#8722;2.3%) for HbA<sub>1c</sub>, &#8722;11.9 mg/dL (95% CI, &#8722;15.8 to &#8722;8.0 mg/dL) for LDL-C, and &#8722;0.1 mm Hg (95% CI, &#8722;1.6 to 1.3 mm Hg) for SBP. The net group differences were &#8722;0.3% (95% CI, &#8722;0.5% to &#8722;0.0%) for HbA<sub>1c</sub>, 0.9 mg/dL (95% CI, &#8722;4.5 to 6.2 mg/dL) for LDL-C, and &#8722;2.4 mm Hg (95% CI, &#8722;4.3 to &#8722;0.4 mm Hg) for SBP (<italic toggle="yes">P</italic>&#8201;=&#8201;.001 for the combined overall effect). The percentage of participants with controlled HbA<sub>1c</sub> among all participants was significantly higher in the intervention group than in the control group at 12 months (195 participants [54.0%] vs 146 participants [46.1%]; <italic toggle="yes">P</italic>&#8201;=&#8201;.04).</p></sec><sec id="ab-zoi250840-10"><title>Conclusions and Relevance</title><p>In this randomized clinical trial of adults with uncontrolled T2D in China, a mobile message&#8211;based intervention resulted in a modest improvement in HbA<sub>1c</sub> and SBP in patients with diabetes compared with usual care. These results suggest that mobile message&#8211;based strategies for improving glycemic control and CVD risk factors should be considered for adults with T2D.</p></sec><sec id="ab-zoi250840-11"><title>Trial Registration</title><p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT03724526?term=NCT03724526&amp;rank=1" ext-link-type="uri">NCT03724526</ext-link></p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="H1-1-ZOI250840"><title>Introduction</title><p>The growing prevalence of type 2 diabetes (T2D) and the consequent cardiovascular disease (CVD) pose a major global health issue. It is estimated that 537 million people had diabetes in 2021, and this number is projected to reach 783 million by 2045.<sup><xref rid="zoi250840r1" ref-type="bibr">1</xref></sup> In China, the prevalence of diabetes in adults aged 20 years or older increased to 12.4% in 2018,<sup><xref rid="zoi250840r2" ref-type="bibr">2</xref></sup> and 86% of Chinese patients with diabetes have multiple comorbid conditions, such as obesity, hypertension, dyslipidemia, and CVD.<sup><xref rid="zoi250840r3" ref-type="bibr">3</xref></sup> Clinical evidence has shown that controlling multiple cardiovascular risk factors lowers the incidence of CVD.<sup><xref rid="zoi250840r4" ref-type="bibr">4</xref>,<xref rid="zoi250840r5" ref-type="bibr">5</xref>,<xref rid="zoi250840r6" ref-type="bibr">6</xref></sup> However, such control remains a clinical challenge as shown by the relatively low proportion of patients with diabetes who have controlled CVD risk factors.<sup><xref rid="zoi250840r7" ref-type="bibr">7</xref></sup> In China, only 5.6% of adults with diabetes have simultaneously achieved therapeutic targets for hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>), blood pressure (BP), and serum cholesterol.<sup><xref rid="zoi250840r8" ref-type="bibr">8</xref></sup></p><p>Barriers for diabetes management, such as lack of health knowledge and motivation to control risk factors, poor adherence to medication therapy, lack of social support, difficulty communicating with physicians, and insufficient time and resources of the health care professional, contribute to poor control of glycemic and CVD risk factors.<sup><xref rid="zoi250840r9" ref-type="bibr">9</xref>,<xref rid="zoi250840r10" ref-type="bibr">10</xref></sup> Mobile health, which is commonly used as a health care delivery strategy to promote health, can address barriers and facilitate disease self-management by directly delivering health information and electronic reminders to patients.<sup><xref rid="zoi250840r11" ref-type="bibr">11</xref>,<xref rid="zoi250840r12" ref-type="bibr">12</xref>,<xref rid="zoi250840r13" ref-type="bibr">13</xref></sup> Accumulating evidence has shown that mobile message&#8211;based interventions improve medication adherence, lifestyle modification, and glycemic control among patients with diabetes.<sup><xref rid="zoi250840r14" ref-type="bibr">14</xref>,<xref rid="zoi250840r15" ref-type="bibr">15</xref>,<xref rid="zoi250840r16" ref-type="bibr">16</xref>,<xref rid="zoi250840r17" ref-type="bibr">17</xref>,<xref rid="zoi250840r18" ref-type="bibr">18</xref>,<xref rid="zoi250840r19" ref-type="bibr">19</xref>,<xref rid="zoi250840r20" ref-type="bibr">20</xref></sup> However, most existing studies have relatively small sample sizes, short intervention times (ie, 3-9 months), and different patterns of text messaging interventions. Importantly, these existing clinical trials of mobile message&#8211;based interventions conducted in populations with diabetes are also focused only on glycemic control rather than on control of multiple CVD risk factors. Indeed, most patients with diabetes require long-term multifactorial therapy to simultaneously reduce multiple risk factors because of their multiple comorbid conditions.<sup><xref rid="zoi250840r4" ref-type="bibr">4</xref>,<xref rid="zoi250840r6" ref-type="bibr">6</xref></sup> Therefore, evaluating the effects of mobile message&#8211;based interventions on reduction of CVD risk factors among patients with diabetes is needed to fill the knowledge gaps. In this randomized clinical trial, we evaluated the effectiveness of a mobile message&#8211;based intervention on CVD risk factor management for patients with uncontrolled T2D.</p></sec><sec id="H1-2-ZOI250840"><title>Methods</title><sec id="H2-1-ZOI250840"><title>Study Design</title><p>This was a multicenter, parallel randomized clinical trial conducted in 5 clinic centers in China. Eligible participants with uncontrolled T2D were randomly assigned to a mobile message&#8211;based intervention or to usual care for 12 months. The primary outcome included the mean changes in HbA<sub>1c</sub> levels, low-density lipoprotein cholesterol (LDL-C) levels, and systolic blood pressure (SBP) levels from baseline to 12 months simultaneously modeled for a single overall treatment effect. The trial protocol is provided in <xref rid="note-ZOI250840-1-s" ref-type="supplementary-material">Supplement 1</xref> and was approved by the ethics committees of Nanfang Hospital of Southern Medical University and the other clinical centers. The trial was conducted in accordance with the principles of the Declaration of Helsinki.<sup><xref rid="zoi250840r21" ref-type="bibr">21</xref></sup> All participants provided written informed consent. This report adhered to the Consolidated Standards of Reporting Trials (<ext-link xlink:href="http://www.equator-network.org/reporting-guidelines/consort/" ext-link-type="uri">CONSORT</ext-link>) reporting guideline.</p></sec><sec id="H2-2-ZOI250840"><title>Participants</title><p>We recruited all the participants during outpatient visits or hospitalization from 5 clinic centers in China between October 2018 and February 2021. Participants were eligible if they were 18 years of age or older with uncontrolled T2D (defined as HbA<sub>1c</sub> &#8805;7.0%, or &#8805;7.5% if combined with clinical CVD [to convert to proportion of total hemoglobin, multiply by 0.01]) comorbid with at least 1 risk factor for CVD (SBP &#8805;140 mm Hg or diastolic BP &#8805;90 mm Hg or LDL-C &#8805;100 mg/dL [to convert to millimoles per liter, multiply by 0.0259]) or clinically diagnosed atherosclerotic CVD (including acute coronary syndrome, ischemic stroke, transient ischemic attack, or peripheral artery disease). All participants had access to a smartphone to read and accept text messages. Exclusion criteria included serious heart failure (New York Heart Association class III to IV), end-stage kidney disease, current or planned pregnancy, and inability to adhere to a 12-month follow-up.</p></sec><sec id="H2-3-ZOI250840"><title>Randomization</title><p>Eligible participants were randomly assigned to either the mobile message&#8211;based intervention or to the control group in a 1:1 ratio. Randomization was stratified by study centers and performed centrally at the Research and Data Coordinating Center in Nanfang Hospital. The randomization schedules were generated using the PROC PLAN procedure in SAS statistical software version 9.4 (SAS Institute) with a block size of 6. Owing to the nature of the intervention, participants were inevitably aware of their group assignments. The research nurses, investigators, and statisticians were blinded to the treatment allocation. The clinical outcomes were also collected by research physicians blinded to the treatment during the study period.</p></sec><sec id="H2-4-ZOI250840"><title>Intervention</title><p>The mobile message&#8211;based intervention was mobile text messages that were regularly delivered by the SMS (short messaging service) platform to remind, encourage, and motivate patients to participate in the behaviors needed for improving glycemic control and CVD risk factor management. Based on recommendations from the Chinese Diabetes Society<sup><xref rid="zoi250840r22" ref-type="bibr">22</xref></sup> and the American Diabetes Association,<sup><xref rid="zoi250840r23" ref-type="bibr">23</xref></sup> a text message bank in plain language was established and modified for Chinese diet, culture, and language habits (text message examples and more details in <xref rid="note-ZOI250840-1-s" ref-type="supplementary-material">Supplement 1</xref>). All messages were in text-compatible 70-character phrases in Chinese. The text message bank covered the following 7 topics: general information about CVD and T2D, healthy diet, physical activity, medication adherence, glucose monitoring, BP control, and smoking cessation. The bank was regularly updated based on newly published guidelines to ensure diversity.</p><p>Participants assigned to the mobile message&#8211;based intervention group received 6 text messages per week from different modules and usual care during the 12-month study period; the control group received usual care. Researchers saved and checked the delivery log to ensure successful delivery. At each visit, participants in the intervention group were asked to confirm or update their phone number and complete a dedicated satisfaction survey questionnaire to investigate the proportion read and satisfaction with the text messages.</p></sec><sec id="H2-5-ZOI250840"><title>Outcomes and Data Collection</title><p>Data were collected from November 2018 to March 2022. The primary outcome comprised the overall mean changes in HbA<sub>1c</sub>, LDL-C, and SBP levels from baseline to 12 months simultaneously modeled for a single overall treatment effect. Secondary outcomes included the proportion of participants with controlled HbA<sub>1c</sub> (&lt;7.0%, or &lt;7.5% for patients with CVD), LDL-C (&lt;100 mg/dL), and BP (&lt;140/90 mm Hg) levels at 12 months, the net change in fasting blood glucose (FBG) levels, total cholesterol levels, triglyceride levels, high-density lipoprotein cholesterol levels, diastolic BP levels, body mass index (BMI, calculated as weight in kilograms divided by height in meters squared), self-reported medication adherence, and health-related quality of life. Medication adherence was measured by the Morisky Medication Adherence Scale (MMAS) (range, 0 to 8, with lower scores indicating lower adherence). Quality of life was measured with the 12-item Short-Form Health Survey Questionnaire. Lifestyle behaviors, including physical activity and daily calorie intake, were also assessed in the study using the International Physical Activity Questionnaire<sup><xref rid="zoi250840r24" ref-type="bibr">24</xref></sup> and a standardized diet questionnaire, respectively.</p><p>Information on sociodemographic factors (age, sex, educational level, and employment status), lifestyle habits (smoking status, drinking status, physical activity, and diet), medication, and medical history was collected by trained staff. Data on physical measurements (height, weight, waist circumference, and BP) were collected at baseline and follow-up visits every 3 months for all participants by trained researchers with the use of standard methods. Measurements of height, weight, and waist circumference were performed in sets of 2 replicates. Sitting BP levels were measured in triplicate after 5 minutes of quiet rest using an automatic electronic sphygmomanometer (Omron). The mean value was used for analysis. Biochemical laboratory tests, including levels of HbA<sub>1c</sub>, FBG, and LDL-C, were measured at the central laboratory according to the manufacturer&#8217;s instructions using 10-hour overnight fasting blood samples at 3-month intervals. Participants in the intervention group were asked to complete a short questionnaire at follow-up about the satisfaction and acceptability of the text messaging intervention. Adverse events were queried during clinical follow-up visits through face-to-face investigation and participant self-report. Notably, due to the impact of the COVID-19 pandemic, the original 2-week follow-up window was extended to 4 weeks during peak pandemic restrictions (January to May 2020).</p></sec><sec id="H2-6-ZOI250840"><title>Statistical Analysis</title><p>We estimated that a sample size of 800 participants would provide 80% power to detect a 5% difference of the net change in standardized overall treatment effect at a significance level of .05 using a 2-tailed test. This result corresponded to a detectable difference of 0.5% in HbA<sub>1c</sub> change (7.2%&#8201;&#177;&#8201;1.6% at baseline), 5 mm Hg in SBP (132&#8201;&#177;&#8201;18 mm Hg at baseline) and 9.7 mg/dL in LDL-C (113.5&#8201;&#177;&#8201;37.1 mg/dL at baseline).<sup><xref rid="zoi250840r15" ref-type="bibr">15</xref>,<xref rid="zoi250840r16" ref-type="bibr">16</xref>,<xref rid="zoi250840r25" ref-type="bibr">25</xref></sup> This sample size allowed for a dropout rate of 20% across 12 months.</p><p>Data were analyzed according to the intention-to-treat principle. Continuous variables are presented as means (SDs) or medians (IQRs), and categorical variables are presented as frequencies with percentages. Group differences in the trial outcomes were evaluated with the use of general linear models for continuous variables and the &#967;<sup>2</sup> test for categorical variables. The overall intervention effect on HbA<sub>1c</sub>, LDL-C, and SBP levels was tested using a scaled marginal model in which each outcome was scaled by its SD. Generalized estimating equations were used to calculate the regression coefficient and outcome-specific scale variables in SAS PROC GENMOD, and the assumption of an overall intervention effect was tested using a score test.<sup><xref rid="zoi250840r26" ref-type="bibr">26</xref></sup> Group differences for the secondary outcomes were also evaluated with the use of generalized estimating equations for continuous variables, adjusting for baseline levels corresponding to each study outcome. In addition, the correlations of outcomes among participants within each clinic center using an exchangeable correlation structure were taken into account in the analysis. Missing data were handled by multiple imputations for a random missingness pattern with the use of the Markov Chain Monte Carlo method.</p><p>Subgroup analyses of HbA<sub>1c</sub>, LDL-C, and SBP levels were conducted by age (&lt;65 or &#8805;65 years), sex (male or female), educational level (junior high school or below, high school or above), employment status (never worked or unemployed, retired, and employed), smoking status (never, former, or current), current alcohol consumption (yes or no), prevalent obesity (yes [BMI &#8805;28] or no [BMI &lt;28]), prevalent hypertension (yes or no), and prevalent hypercholesterolemia (yes or no). Analyses were conducted from January to June 2023 using SAS version 9.4 (SAS Institute). A 2-sided <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.05 was considered to indicate statistical significance for the outcomes.</p></sec></sec><sec id="H1-3-ZOI250840"><title>Results</title><p>Between October 2018 and February 2021, a total of 2782 patients with diagnosed T2D were screened for eligibility. Of these, 819 participants were enrolled from 5 clinic centers and randomly assigned to the intervention (n&#8201;=&#8201;410) or control group (n&#8201;=&#8201;409) (<xref rid="zoi250840f1" ref-type="fig">Figure 1</xref>). In total, 361 participants (88.0%) in the intervention group and 317 participants (77.5%) in the control group completed the 12-month intervention. Their mean (SD) age was 50.1 (11.9) years; 552 (67.4%) were male and 267 (32.6%) were female. Their mean (SD) HbA<sub>1c</sub> level was 10.2% (2.1%), mean (SD) SBP was 126.9 (14.0) mm Hg, and mean (SD) LDL-C level was 129.8 (34.5) mg/dL. Baseline characteristics of the study participants were similar between the 2 groups (<xref rid="zoi250840t1" ref-type="table">Table 1</xref>).</p><fig position="float" id="zoi250840f1" fig-type="figure" orientation="portrait"><label>Figure 1. </label><caption><title>Flowchart of Trial Participants</title></caption><graphic position="float" orientation="portrait" xlink:href="jamanetwopen-e2529762-g001.jpg"/></fig><table-wrap position="float" id="zoi250840t1" orientation="portrait"><label>Table 1. </label><caption><title>Characteristics of the Participants at Baseline</title></caption><table frame="hsides" rules="groups"><col width="45.83%" span="1"/><col width="29.11%" span="1"/><col width="25.06%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="rowgroup" colspan="1">Characteristic</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Participants, No. (%)<sup>a</sup></th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Intervention group (n&#8201;=&#8201;410)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Control group (n&#8201;=&#8201;409)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td><td valign="top" align="left" rowspan="1" colspan="1">125 (30.5)</td><td valign="top" align="left" rowspan="1" colspan="1">142 (34.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td><td valign="top" align="left" rowspan="1" colspan="1">285 (69.5)</td><td valign="top" align="left" rowspan="1" colspan="1">267 (65.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, mean (SD), y</td><td valign="top" align="left" rowspan="1" colspan="1">49.4 (12.2)</td><td valign="top" align="left" rowspan="1" colspan="1">50.8 (11.6)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Marital status</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Single</td><td valign="top" align="left" rowspan="1" colspan="1">19 (4.6)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (3.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Married or cohabited</td><td valign="top" align="left" rowspan="1" colspan="1">379 (92.4)</td><td valign="top" align="left" rowspan="1" colspan="1">376 (91.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Separated</td><td valign="top" align="left" rowspan="1" colspan="1">6 (1.5)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (1.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Widowed</td><td valign="top" align="left" rowspan="1" colspan="1">6 (1.5)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (2.4)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Highest formal educational level</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> None</td><td valign="top" align="left" rowspan="1" colspan="1">7 (1.7)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (2.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Primary school</td><td valign="top" align="left" rowspan="1" colspan="1">61 (14.9)</td><td valign="top" align="left" rowspan="1" colspan="1">64 (15.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Junior high school</td><td valign="top" align="left" rowspan="1" colspan="1">102 (24.9)</td><td valign="top" align="left" rowspan="1" colspan="1">133 (32.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Senior high school or technical college</td><td valign="top" align="left" rowspan="1" colspan="1">115 (28.1)</td><td valign="top" align="left" rowspan="1" colspan="1">107 (26.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> College or university undergraduate</td><td valign="top" align="left" rowspan="1" colspan="1">118 (28.8)</td><td valign="top" align="left" rowspan="1" colspan="1">86 (21.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> University postgraduate</td><td valign="top" align="left" rowspan="1" colspan="1">7 (1.7)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (1.7)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Employment status</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Never worked or unemployed</td><td valign="top" align="left" rowspan="1" colspan="1">41 (10.0)</td><td valign="top" align="left" rowspan="1" colspan="1">55 (13.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Retired</td><td valign="top" align="left" rowspan="1" colspan="1">118 (28.8)</td><td valign="top" align="left" rowspan="1" colspan="1">112 (27.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Employed</td><td valign="top" align="left" rowspan="1" colspan="1">251 (61.2)</td><td valign="top" align="left" rowspan="1" colspan="1">242 (59.2)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Smoking status</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Never</td><td valign="top" align="left" rowspan="1" colspan="1">215 (52.4)</td><td valign="top" align="left" rowspan="1" colspan="1">229 (56.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Former</td><td valign="top" align="left" rowspan="1" colspan="1">68 (16.6)</td><td valign="top" align="left" rowspan="1" colspan="1">68 (16.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Current</td><td valign="top" align="left" rowspan="1" colspan="1">127 (31.0)</td><td valign="top" align="left" rowspan="1" colspan="1">112 (27.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Current alcohol consumption</td><td valign="top" align="left" rowspan="1" colspan="1">69 (16.8)</td><td valign="top" align="left" rowspan="1" colspan="1">67 (16.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Body weight, mean (SD), kg</td><td valign="top" align="left" rowspan="1" colspan="1">68.9 (11.7)</td><td valign="top" align="left" rowspan="1" colspan="1">67.6 (12.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">BMI, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">25.2 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">25.0 (3.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Waist circumference, mean (SD), cm</td><td valign="top" align="left" rowspan="1" colspan="1">89.8 (9.0)</td><td valign="top" align="left" rowspan="1" colspan="1">89.2 (10.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Systolic blood pressure, mean (SD), mm Hg</td><td valign="top" align="left" rowspan="1" colspan="1">127.5 (14.5)</td><td valign="top" align="left" rowspan="1" colspan="1">126.2 (13.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Diastolic blood pressure, mean (SD), mm Hg</td><td valign="top" align="left" rowspan="1" colspan="1">78.9 (9.7)</td><td valign="top" align="left" rowspan="1" colspan="1">77.8 (8.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Fasting glucose, mean (SD), mg/dL</td><td valign="top" align="left" rowspan="1" colspan="1">176.2 (88.5)</td><td valign="top" align="left" rowspan="1" colspan="1">176.4 (90.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hemoglobin A<sub>1c</sub>, mean (SD), %</td><td valign="top" align="left" rowspan="1" colspan="1">10.1 (2.0)</td><td valign="top" align="left" rowspan="1" colspan="1">10.3 (2.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Total cholesterol, mean (SD), mg/dL</td><td valign="top" align="left" rowspan="1" colspan="1">202.2 (46.6)</td><td valign="top" align="left" rowspan="1" colspan="1">202.0 (45.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Triglyceride, median (IQR), mg/dL</td><td valign="top" align="left" rowspan="1" colspan="1">143.8 (100.0-220.4)</td><td valign="top" align="left" rowspan="1" colspan="1">140.7 (98.2-207.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">LDL-C, mean (SD), mg/dL</td><td valign="top" align="left" rowspan="1" colspan="1">129.7 (34.9)</td><td valign="top" align="left" rowspan="1" colspan="1">129.8 (34.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HDL-C, mean (SD), mg/dL</td><td valign="top" align="left" rowspan="1" colspan="1">42.6 (10.7)</td><td valign="top" align="left" rowspan="1" colspan="1">43.8 (12.3)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">SF-12, mean (SD), score<sup>b</sup></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Physical component summary</td><td valign="top" align="left" rowspan="1" colspan="1">42.0 (5.8)</td><td valign="top" align="left" rowspan="1" colspan="1">41.5 (6.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mental component summary</td><td valign="top" align="left" rowspan="1" colspan="1">47.0 (5.0)</td><td valign="top" align="left" rowspan="1" colspan="1">47.2 (5.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Patient Health Questionnaire-9, median (IQR), score<sup>c</sup></td><td valign="top" align="left" rowspan="1" colspan="1">3 (0-6)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (1-6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">History of hypertension</td><td valign="top" align="left" rowspan="1" colspan="1">142 (34.6)</td><td valign="top" align="left" rowspan="1" colspan="1">139 (34.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">History of CVD</td><td valign="top" align="left" rowspan="1" colspan="1">148 (36.1)</td><td valign="top" align="left" rowspan="1" colspan="1">139 (34.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">History of dyslipidemia</td><td valign="top" align="left" rowspan="1" colspan="1">272 (66.3)</td><td valign="top" align="left" rowspan="1" colspan="1">266 (65.0)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Medication</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Antihyperglycemic agent</td><td valign="top" align="left" rowspan="1" colspan="1">259 (63.2)</td><td valign="top" align="left" rowspan="1" colspan="1">273 (66.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Antihypertensive drug</td><td valign="top" align="left" rowspan="1" colspan="1">106 (25.9)</td><td valign="top" align="left" rowspan="1" colspan="1">99 (24.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lipid-lowering agent</td><td valign="top" align="left" rowspan="1" colspan="1">61 (14.9)</td><td valign="top" align="left" rowspan="1" colspan="1">71 (17.4)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SF-12, 12-item Short-Form Health Survey Questionnaire.</p><p>SI conversion factors: To convert cholesterol, fasting blood glucose, and triglyceride levels to millimoles per liter, multiply values by 0.0259, 0.0555, and 0.0113, respectively; hemoglobin A<sub>1c</sub> to proportion of total hemoglobin, multiply by 0.01.</p><fn id="zoi250840t1n1"><label>
<sup>a</sup>
</label><p>Percentages may not total 100 because of rounding.</p></fn><fn id="zoi250840t1n2"><label>
<sup>b</sup>
</label><p>The SF-12 measures health-related quality of life and includes a physical composite score and a mental composite score, each ranging from 0 to 100, with higher scores indicating better states of health.</p></fn><fn id="zoi250840t1n3"><label>
<sup>c</sup>
</label><p>Patient Health Questionnaire-9 scores ranged from 0 to 27, with higher values indicating greater depression severity.</p></fn></table-wrap-foot></table-wrap><sec id="H2-7-ZOI250840"><title>Primary Outcomes</title><p>The mobile message&#8211;based intervention had a significant overall improvement on the mean changes in HbA<sub>1c </sub>(&#8722;3.0% [95% CI, &#8722;0.5% to &#8722;0.0%]), LDL-C (0.9mg/dL [95% CI, &#8722;4.5 to 6.2 mg/dL]), and SBP (&#8722;2.4mm Hg [95% CI, &#8722;4.3 to &#8722;0.4mm Hg]) levels at 12 months (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001 for the combined overall effect). HbA<sub>1c</sub> levels and LDL-C levels significantly decreased from baseline to 12 months in both groups, whereas SBP levels did not (<xref rid="zoi250840t2" ref-type="table">Table 2</xref>). Significant reductions in the mobile message&#8211;based intervention group were observed for HbA<sub>1c</sub> levels by &#8722;2.8% (95% CI, &#8722;2.9% to &#8722;2.6%), LDL-C by &#8722;11.1 mg/dL (95% CI, &#8722;14.7 to &#8722;7.4 mg/dL), and SBP by &#8722;2.5 mm Hg (95% CI, &#8722;3.9 to &#8722;1.2 mm Hg), and in the usual care group by &#8722;2.5% (95% CI, &#8722;2.7% to &#8722;2.3%) for HbA<sub>1c</sub>, &#8722;11.9 mg/dL (95% CI, &#8722;15.8 to &#8722;8.0 mg/dL) for LDL-C, and &#8722;0.1 mm Hg (95% CI, &#8722;1.6 to 1.3 mm Hg) for SBP. The net group differences for the 6-month changes were &#8722;0.4% (95% CI, &#8722;0.6 to &#8722;0.2%) for HbA<sub>1c</sub>, 2.8 mg/dL (95% CI, &#8722;2.6 to 8.2 mg/dL) for LDL-C, and &#8722;2.3 mm Hg (95% CI, &#8722;4.2 to &#8722;0.3 mm Hg) for SBP (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001 for the combined overall effect). In a sensitivity analyses using multiple imputed data, the overall improvements of the mobile message&#8211;based intervention on the mean changes in HbA<sub>1c</sub> levels, LDL-C levels, and SBP levels were similar and significant for the combined overall effect. The group difference in the reduction in HbA<sub>1c</sub> level was &#8722;0.2% (95% CI, &#8722;0.5% to &#8722;0.0%), in LDL-C level was 0.7 mg/dL (95% CI, &#8722;4.7 to 6.2 mg/dL), and in SBP level was &#8722;2.3 mm Hg (95% CI, &#8722;4.3 to &#8722;0.4 mm Hg) across 12 months (eTable 1 in <xref rid="note-ZOI250840-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p><table-wrap position="float" id="zoi250840t2" orientation="portrait"><label>Table 2. </label><caption><title>Primary and Secondary End Point Analyses at 6 and 12 Months of Follow-Up Without Imputation for Missing Data</title></caption><table frame="hsides" rules="groups"><col width="30.46%" span="1"/><col width="21.15%" span="1"/><col width="17.16%" span="1"/><col width="21.23%" span="1"/><col width="10%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="rowgroup" colspan="1">Study outcome</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Group, change (95% CI)<xref rid="zoi250840t2n1" ref-type="table-fn"><sup>a</sup></xref></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Difference between groups, change (95% CI)<xref rid="zoi250840t2n2" ref-type="table-fn"><sup>b</sup></xref></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic toggle="yes">P</italic> value</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Intervention (n&#8201;=&#8201;361)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Control (n&#8201;=&#8201;317)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">
<bold>Primary outcomes at 12 mo</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Change in hemoglobin A<sub>1c</sub>, %</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;2.8 (&#8722;2.9 to &#8722;2.6)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;2.5 (&#8722;2.7 to &#8722;2.3)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.3 (&#8722;0.5 to &#8722;0.0)</td><td valign="top" align="left" rowspan="1" colspan="1">.03</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Change in LDL-C, mg/dL</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;11.1 (&#8722;14.7 to &#8722;7.4)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;11.9 (&#8722;15.8 to &#8722;8.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.9 (&#8722;4.5 to 6.2)</td><td valign="top" align="left" rowspan="1" colspan="1">.75</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Change in systolic BP, mm Hg</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;2.5 (&#8722;3.9 to &#8722;1.2)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.1 (&#8722;1.6 to 1.3)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;2.4 (&#8722;4.3 to &#8722;0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">.02</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">
<bold>Primary outcomes at 6 mo<xref rid="zoi250840t2n3" ref-type="table-fn"><sup>c</sup></xref></bold>
</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Change in hemoglobin A<sub>1c</sub>, %</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;3.1 (&#8722;3.2 to &#8722;2.9)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;2.7 (&#8722;2.9 to &#8722;2.5)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.4 (&#8722;0.6 to &#8722;0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Change in LDL-C, mg/dL</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;10.8 (&#8722;14.5 to &#8722;7.1)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;13.6 (&#8722;17.5 to &#8722;9.7)</td><td valign="top" align="left" rowspan="1" colspan="1">2.8 (&#8722;2.6 to 8.2)</td><td valign="top" align="left" rowspan="1" colspan="1">.31</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Change in systolic BP, mm Hg</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;3.2 (&#8722;4.5 to &#8722;1.8)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.9 (&#8722;2.3 to 0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;2.3 (&#8722;4.2 to &#8722;0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">.03</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">
<bold>Secondary outcomes</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Change in fasting plasma glucose, mmol/L</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 6 mo</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;42.5 (&#8722;48.3 to &#8722;36.6)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;32.1 (&#8722;38.4 to &#8722;25.8)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;10.5 (&#8722;19.1 to &#8722;1.8)</td><td valign="top" align="left" rowspan="1" colspan="1">.02</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 12 mo</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;33.0 (&#8722;38.4 to &#8722;27.4)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;26.8 (&#8722;32.8 to &#8722;21.1)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;5.9 (&#8722;14.1 to 2.2)</td><td valign="top" align="left" rowspan="1" colspan="1">.15</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Change in total cholesterol, mg/dL</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 6 mo</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;16.9 (&#8722;21.5 to &#8722;12.4)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;15.7 (&#8722;20.5 to &#8722;10.9)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;1.2 (&#8722;7.8 to 5.4)</td><td valign="top" align="left" rowspan="1" colspan="1">.71</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 12 mo</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;12.9 (&#8722;17.3 to &#8722;8.4)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;13.6 (&#8722;18.4 to &#8722;8.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.7 (&#8722;5.8 to 7.3)</td><td valign="top" align="left" rowspan="1" colspan="1">.82</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Change in triglycerides, mg/dL</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 6 mo</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;28.9 (&#8722;48.3 to &#8722;9.6)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;9.6 (&#8722;29.9 to 10.8)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;19.4 (&#8722;47.4 to 8.6)</td><td valign="top" align="left" rowspan="1" colspan="1">.18</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 12 mo</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;16.0 (&#8722;35.0 to 3.0)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;5.0 (&#8722;25.3 to 15.2)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;11.0 (&#8722;38.8 to 16.8)</td><td valign="top" align="left" rowspan="1" colspan="1">.44</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Change in HDL-C, mg/dL</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 6 mo</td><td valign="top" align="left" rowspan="1" colspan="1">2.9 (2.0 to 3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">3.3 (2.4 to 4.3)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.4 (&#8722;1.8 to 1.0)</td><td valign="top" align="left" rowspan="1" colspan="1">.56</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 12 mo</td><td valign="top" align="left" rowspan="1" colspan="1">3.2 (2.2 to 4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">3.1 (2.2 to 4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.0 (&#8722;1.3 to 1.4)</td><td valign="top" align="left" rowspan="1" colspan="1">.96</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Change in diastolic BP, mm Hg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 6 mo</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;1.8 (&#8722;2.7 to &#8722;0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.8 (&#8722;1.7 to 0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;1.0 (&#8722;2.3 to 0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">.10</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 12 mo</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;1.4 (&#8722;2.3 to &#8722;0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.6 (&#8722;1.5 to 0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.9 (&#8722;2.1 to 0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">.17</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Change in BMI</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 6 mo</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.2 (&#8722;0.4 to &#8722;0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.2 (&#8722;0.4 to &#8722;0.0)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.0 (&#8722;0.3 to 0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">.79</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 12 mo</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.1 (&#8722;0.2 to 0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.0 (&#8722;0.2 to 0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.0 (&#8722;0.3 to 0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">.78</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Participants with controlled hemoglobin A<sub>1c</sub> at 12 mo, No. (%)</td><td valign="top" align="left" rowspan="1" colspan="1">195 (54.0)</td><td valign="top" align="left" rowspan="1" colspan="1">146 (46.1)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">.04</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Participants with LDL-C &lt;100 mg/dL at 12 mo, No. (%)</td><td valign="top" align="left" rowspan="1" colspan="1">118 (32.7)</td><td valign="top" align="left" rowspan="1" colspan="1">106 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">.86</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Participants with BP &lt;140/90 mm Hg at 12 mo, No. (%)</td><td valign="top" align="left" rowspan="1" colspan="1">294 (80.8)</td><td valign="top" align="left" rowspan="1" colspan="1">242 (76.8)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">.21</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NA, not applicable.</p><p>SI conversion factors: To convert cholesterol, fasting blood glucose, and triglyceride levels to millimoles per liter, multiply values by 0.0259, 0.0555, and 0.0113, respectively; hemoglobin A<sub>1c</sub> to proportion of total hemoglobin, multiply by 0.01.</p><fn id="zoi250840t2n1"><label>
<sup>a</sup>
</label><p>Participant numbers reported here represent those included in the 12-month follow-up analysis.</p></fn><fn id="zoi250840t2n2"><label>
<sup>b</sup>
</label><p>The difference in single study outcome between groups was tested using a mixed-effects model in PROC MIXED, with randomized treatment as a factor and baseline end point value or clinic center as a covariate.</p></fn><fn id="zoi250840t2n3"><label>
<sup>c</sup>
</label><p>At the 6-month follow-up, the analysis included 349 participants in the intervention group and 321 in the control group.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H2-8-ZOI250840"><title>Secondary Outcomes</title><p>The percentage of participants with controlled HbA<sub>1c</sub> was significantly higher in the intervention group than in the control group at 12 months (195 participants [54.0%] vs 146 participants [46.1%]; <italic toggle="yes">P</italic>&#8201;=&#8201;.04). There were no significant group differences in the percentages of patients with controlled LDL-C (118 [32.7%] vs106 [33.3%]; <italic toggle="yes">P</italic>&#8201;=&#8201;.86) and SBP (294 [80.8%] vs 242 [76.8%]; <italic toggle="yes">P</italic>&#8201;=&#8201;.21) (<xref rid="zoi250840t2" ref-type="table">Table 2</xref>). The FBG levels at the 6-month follow-up were lower in the intervention group compared with the control group, with a mean difference of &#8722;10.5 mg/dL (95% CI, &#8722;19.1 to 1.8 mg/dL [to convert to millimoles per liter, multiply by 0.0555]; <italic toggle="yes">P</italic>&#8201;=&#8201;.02), but the net difference was no longer statistically significant at 12 months (&#8722;5.9 mg/dL [95% CI, &#8722;14.1 to 2.2 mg/dL]; <italic toggle="yes">P</italic>&#8201;=&#8201;.15). There was no significantly greater reduction in waist circumference, weight, BMI, diastolic BP, or lipid levels (ie, total cholesterol, triglyceride, and high-density lipoprotein cholesterol) in the intervention group than in the control group across 12 months (<xref rid="zoi250840t2" ref-type="table">Table 2</xref>; eFigures 1 and 2 in <xref rid="note-ZOI250840-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p><p><xref rid="zoi250840f2" ref-type="fig">Figure 2</xref> shows the absolute HbA<sub>1c</sub>, LDL-C, and SBP levels as well as the percentages of participants with all 3 risk factors controlled across the 12-month intervention. The differences between the groups in mean HbA<sub>1c</sub> and SBP levels were significant during the 12 months, whereas the group difference in LDL-C levels was not. Furthermore, there were no significant differences in the percentages of participants with all 3 risk factors controlled between the 2 groups at 6 and 12 months. In addition, changes in HbA<sub>1c</sub>, LDL-C, and SBP levels were similar for the 2 groups when assessed by subgroup (ie, sex, educational level, smoking or drinking status, BMI at baseline, and presence of hypercholesterolemia) (eTables 2-4 in <xref rid="note-ZOI250840-1-s" ref-type="supplementary-material">Supplement 2</xref>). The reduction in HbA<sub>1c</sub> levels was greater in participants younger than 65 years, whereas the reduction in SBP levels was greater in participants aged 65 years or older.</p><fig position="float" id="zoi250840f2" fig-type="figure" orientation="portrait"><label>Figure 2. </label><caption><title>Absolute Hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>), Low-Density Lipoprotein Cholesterol (LDL-C), Systolic Blood Pressure (BP) Levels, and Percentages of Participants With All 3 Risk Factors Controlled for Intervention and Control Groups</title><p>Error bars represent SEs for means. To convert cholesterol to millimoles per liter, multiply by 0.0259; hemoglobin A<sub>1c</sub> to proportion of total hemoglobin, multiply by 0.01.</p></caption><graphic position="float" orientation="portrait" xlink:href="jamanetwopen-e2529762-g002.jpg"/></fig><p>Daily total calorie intake in both groups decreased significantly from baseline to 6 and 12 months, particularly in the intervention group, but there was no statistically significant difference between the 2 groups (eTable 5 in <xref rid="note-ZOI250840-1-s" ref-type="supplementary-material">Supplement 2</xref>). The proportions of carbohydrate, protein, and fat intake were similar in both groups. In addition, there were no significant differences in daily physical activity, MMAS scores, and physical and mental composite scores measured with the 12-item Short-Form Health Survey Questionnaire. The percentage of participants receiving glucose-lowering therapy and the number of antihyperglycemic used in the intervention group were significantly higher than those in the control group (eTable 6 in <xref rid="note-ZOI250840-1-s" ref-type="supplementary-material">Supplement 2</xref>). By contrast, no significant differences were observed in the percentage of participants receiving BP-lowering or lipid-lowering therapy or the number of lipid-lowering agents.</p></sec><sec id="H2-9-ZOI250840"><title>Adverse Events</title><p>Two deaths and 1 fracture event were reported during the trial. One participant in the control group started dialysis treatment during the 12-month trial. No other adverse events occurred in either group.</p></sec></sec><sec id="H1-4-ZOI250840"><title>Discussion</title><p>In this 12-month multicenter randomized clinical trial, a mobile message&#8211;based intervention significantly but modestly reduced HbA<sub>1c</sub> and SBP levels compared with usual care. Mobile health interventions have gained much attention owing to affordability and ability to deliver health services, particularly in developing or low-income countries. Mobile phone text messages have potential to promote CVD risk factor control, but high-quality evidence regarding control of multiple CVD risk factors as primary outcomes is still limited. The TEXT-ME (Tobacco, Exercise and Diet Messages) study conducted in a single-center in Australia, showed that the use of a lifestyle-focused text messaging intervention compared with usual care resulted in a modest reduction in LDL-C level as a primary outcome, and moderate improvements in SBP, BMI and smoking status in patients with coronary heart disease (CHD) across 6 months.<sup><xref rid="zoi250840r15" ref-type="bibr">15</xref></sup> In the present trial, we developed a culturally adapted, content-enhanced mobile message&#8211;based module for a multifactor intervention in patients with diabetes and assessed the long-term common effect of the mobile message&#8211;based intervention on the control of multiple CVD risk factors. The text messaging intervention resulted in a statistically significant overall improvement in HbA<sub>1c</sub>, LDL-C, and SBP levels at 12 months in patients with uncontrolled T2D. A plausible mechanism underlying these interventions may be through more patient receipt intensive medication. This finding is encouraging for future studies of mobile text messaging to support secondary prevention goals in the management of diabetes. This finding may also have important public health and clinical importance for management of multiple risk factors in patients with diabetes.</p><p>Our findings are consistent with the existing evidence that supports the effectiveness of mobile phone text messaging for improving key CVD risk factors. A number of randomized clinical trials have shown improvements in weight loss, glycemic control, lipid, and BP lowering in diabetes and diagnosed CHD.<sup><xref rid="zoi250840r15" ref-type="bibr">15</xref>,<xref rid="zoi250840r17" ref-type="bibr">17</xref>,<xref rid="zoi250840r19" ref-type="bibr">19</xref>,<xref rid="zoi250840r27" ref-type="bibr">27</xref></sup> In contrast, other studies have failed to detect significant effectiveness of mobile phone text messaging interventions in the improvement of SBP and LDL-C levels among patients with both diagnosed CHD and diabetes in China.<sup><xref rid="zoi250840r18" ref-type="bibr">18</xref>,<xref rid="zoi250840r28" ref-type="bibr">28</xref></sup> One important difference between these 2 latter studies and the current study is that our study targeted multiple risk factors rather than individual risk factors, as the primary outcome was overall improvement in 3 risk factors (HbA<sub>1c</sub>, LDL-C, and SBP levels). In addition, our follow-up time was longer than that of all the aforementioned studies. For BP as individual outcome, our trial showed that the SBP level was significantly reduced in the mobile message&#8211;based intervention compared with usual care across 12 months. To our knowledge, this is the first trial to investigate the long-term effect of a mobile message&#8211;based intervention on BP control in patients with diabetes.</p><p>Numerous studies have assessed the mobile message&#8211;based intervention on glycemic control in patients with diabetes, but the results have been inconsistent.<sup><xref rid="zoi250840r14" ref-type="bibr">14</xref>,<xref rid="zoi250840r16" ref-type="bibr">16</xref>,<xref rid="zoi250840r17" ref-type="bibr">17</xref>,<xref rid="zoi250840r18" ref-type="bibr">18</xref></sup> For instance, the text message&#8211;based diabetes self-management support program SMS4BG study reported that the intervention resulted in modest improvements in glycemic control in adults with uncontrolled diabetes.<sup><xref rid="zoi250840r29" ref-type="bibr">29</xref></sup> In contrast, the REACH (Rapid Education/Encouragement and Communications for Health) study showed a short-term effect of improved HbA<sub>1c</sub> but no sustained effect at 15 months.<sup><xref rid="zoi250840r19" ref-type="bibr">19</xref></sup> One meta-analysis of 5 clinical trials showed no statistically significant effect of mobile text messaging on physical activity, glycemic control, weight, or BMI among patients with T2D.<sup><xref rid="zoi250840r30" ref-type="bibr">30</xref></sup> The discrepancy across studies may be due to small sample sizes, short intervention times (ie, 3-9 months), heterogeneity in the frequency of text message transmission, and different patterns of text message&#8211;based intervention. Our findings suggest that mobile text messaging helps to address the gap in evidence by showing that delivery of motivational reminders and health information via text message is possible and effective in diabetes management. Sahin et al<sup><xref rid="zoi250840r31" ref-type="bibr">31</xref></sup> conducted a systematic review and meta-analysis to explore optimal tailoring strategies, message design, and delivery features of mobile text messaging and reported that a direct and personalized communication and tailored interventions with 1-way messaging could be more effective than 2-way messages. In the present trial, we found that there was a modest reduction of 2.8% in HbA<sub>1c</sub> in the intervention group, and a significant net difference of &#8722;0.3% between the groups at 12 months. The magnitude of improvement in HbA<sub>1c</sub> observed in this study is consistent with the average reduction reported in previous studies,<sup><xref rid="zoi250840r14" ref-type="bibr">14</xref>,<xref rid="zoi250840r16" ref-type="bibr">16</xref>,<xref rid="zoi250840r18" ref-type="bibr">18</xref>,<xref rid="zoi250840r32" ref-type="bibr">32</xref>,<xref rid="zoi250840r33" ref-type="bibr">33</xref></sup> which would potentially limit the clinical value of nontailored and standardized text message intervention. Future large-scale, longer-term studies of tailored 1-way text message intervention are needed to determine its effectiveness in controlling cardiovascular risk factors in populations with T2D.</p><p>We did not detect differences between groups in LDL-C and BMI, which is consistent with the CHAT-DM (Cardiovascular Health and Text Messaging&#8211;Diabetes Mellitus) trial.<sup><xref rid="zoi250840r25" ref-type="bibr">25</xref></sup> Our study enrolled patients with diabetes although it did not restrict inclusion to individuals with uncontrolled hyperlipidemia, which may explain the lack of effect on LDL-C levels. Moreover, our data showed that there was no significant reduction in caloric intake or the proportion of fat intake in either group and no significant difference in lipid-lowering medication and physical activity between the 2 groups, which may explain the negative results. Future mobile message&#8211;based interventions should strengthen education in the adjustment of the diet structure, especially the control of fat intake and blood lipid management. Future studies are needed to further determine if the effects of text messaging intervention on the control of these risk factors can be enhanced and sustained, especially when integrated into clinical practice.</p><sec id="H2-10-ZOI250840"><title>Limitations</title><p>This study has limitations. First, the primary outcomes were changes in the levels of risk factors (HbA<sub>1c</sub>, LDL-C, and BP) rather than clinical outcomes. However, we can infer from the literature<sup><xref rid="zoi250840r34" ref-type="bibr">34</xref>,<xref rid="zoi250840r35" ref-type="bibr">35</xref></sup> that changes in risk factors can affect future clinical outcomes if they are sustained. Second, the intervention only targeted patient-initiated behavior change; however, the geographic and clinical characteristics of the patients may have improved the effectiveness of the intervention. Interventions aimed at both patients and health care professionals could be helpful to minimize the gap between guidelines and clinical practice. Third, behavioral outcomes in this trial were assessed through either self-reported measures or structured investigator-administered questionnaires, which may be subject to recall bias. Fourth, the lack of systematic data on participants&#8217; health care utilization frequency precluded analysis of potential text message intervention effects on clinical visit patterns. Additionally, this study did not determine the value of the intervention using a cost-effectiveness analysis. A future cost-effectiveness analysis is needed to determine the value of the intervention.</p></sec></sec><sec id="H1-5-ZOI250840"><title>Conclusions</title><p>In this randomized clinical trial of adults with uncontrolled T2D in China, a mobile message&#8211;based intervention resulted in a modest improvement in HbA<sub>1c</sub> levels and BP among patients with uncontrolled T2D compared with usual care. These findings suggest that mobile message&#8211;based strategies for improving glycemic control and CVD risk factors should be considered for adults with T2D.</p></sec></body><back><ref-list id="REF-ZOI250840"><title>References</title><ref id="zoi250840r1"><label>1</label><mixed-citation publication-type="book"><person-group><collab>International Diabetes Federation</collab></person-group>. <source>IDF Diabetes Atlas</source>. <edition>10th ed</edition>. <publisher-name>International Diabetes Federation</publisher-name>; <year>2021</year>.</mixed-citation></ref><ref id="zoi250840r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></string-name>, <etal/></person-group>. <article-title>Prevalence and treatment of diabetes in China, 2013-2018</article-title>. <source>JAMA</source>. <year>2021</year>;<volume>326</volume>(<issue>24</issue>):<fpage>2498</fpage>-<lpage>2506</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2021.22208</pub-id><pub-id pub-id-type="pmid">34962526</pub-id><pub-id pub-id-type="pmcid">PMC8715349</pub-id></mixed-citation></ref><ref id="zoi250840r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Yang</surname><given-names>ZJ</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>ZG</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>WY</given-names></string-name>; <collab>China National Diabetes and Metabolic Disorders Study Group</collab></person-group>. <article-title>Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and Metabolic Disorders Study</article-title>. <source>Eur Heart J</source>. <year>2012</year>;<volume>33</volume>(<issue>2</issue>):<fpage>213</fpage>-<lpage>220</lpage>. doi:<pub-id pub-id-type="doi">10.1093/eurheartj/ehr205</pub-id><pub-id pub-id-type="pmid">21719451</pub-id></mixed-citation></ref><ref id="zoi250840r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Janssen</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Gorter</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Stolk</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Rutten</surname><given-names>GE</given-names></string-name></person-group>. <article-title>Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study</article-title>. <source>Br J Gen Pract</source>. <year>2009</year>;<volume>59</volume>(<issue>558</issue>):<fpage>43</fpage>-<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.3399/bjgp09X394851</pub-id><pub-id pub-id-type="pmid">19105915</pub-id><pub-id pub-id-type="pmcid">PMC2605530</pub-id></mixed-citation></ref><ref id="zoi250840r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Ueki</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sasako</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Okazaki</surname><given-names>Y</given-names></string-name>, <etal/>; <collab>J-DOIT3 Study Group</collab></person-group>. <article-title>Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2017</year>;<volume>5</volume>(<issue>12</issue>):<fpage>951</fpage>-<lpage>964</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-8587(17)30327-3</pub-id><pub-id pub-id-type="pmid">29079252</pub-id></mixed-citation></ref><ref id="zoi250840r6"><label>6</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Gaede</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lund-Andersen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Parving</surname><given-names>HH</given-names></string-name>, <string-name name-style="western"><surname>Pedersen</surname><given-names>O</given-names></string-name></person-group>. <article-title>Effect of a multifactorial intervention on mortality in type 2 diabetes</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>358</volume>(<issue>6</issue>):<fpage>580</fpage>-<lpage>591</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa0706245</pub-id><pub-id pub-id-type="pmid">18256393</pub-id></mixed-citation></ref><ref id="zoi250840r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Chow</surname><given-names>CK</given-names></string-name>, <string-name name-style="western"><surname>Jolly</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rao-Melacini</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Anand</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Yusuf</surname><given-names>S</given-names></string-name></person-group>. <article-title>Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>121</volume>(<issue>6</issue>):<fpage>750</fpage>-<lpage>758</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.891523</pub-id><pub-id pub-id-type="pmid">20124123</pub-id></mixed-citation></ref><ref id="zoi250840r8"><label>8</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Ji</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>C</given-names></string-name>, <etal/></person-group> Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. <source>Am J Med</source>. <year>2013</year>;126(10):925.e11-925.e22. doi:<pub-id pub-id-type="doi">10.1016/j.amjmed.2013.02.035</pub-id><pub-id pub-id-type="pmid">23810406</pub-id></mixed-citation></ref><ref id="zoi250840r9"><label>9</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Nam</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chesla</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Stotts</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Kroon</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Janson</surname><given-names>SL</given-names></string-name></person-group>. <article-title>Barriers to diabetes management: patient and provider factors</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2011</year>;<volume>93</volume>(<issue>1</issue>):<fpage>1</fpage>-<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.diabres.2011.02.002</pub-id><pub-id pub-id-type="pmid">21382643</pub-id></mixed-citation></ref><ref id="zoi250840r10"><label>10</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Rodriguez</surname><given-names>KM</given-names></string-name></person-group>. <article-title>Intrinsic and extrinsic factors affecting patient engagement in diabetes self-management: perspectives of a certified diabetes educator</article-title>. <source>Clin Ther</source>. <year>2013</year>;<volume>35</volume>(<issue>2</issue>):<fpage>170</fpage>-<lpage>178</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clinthera.2013.01.002</pub-id><pub-id pub-id-type="pmid">23411000</pub-id></mixed-citation></ref><ref id="zoi250840r11"><label>11</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Dobson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Whittaker</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pfaeffli Dale</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Maddison</surname><given-names>R</given-names></string-name></person-group>. <article-title>The effectiveness of text message-based self-management interventions for poorly-controlled diabetes: a systematic review</article-title>. <source>Digit Health</source>. Published online November 9, <year>2017</year>. doi:<pub-id pub-id-type="doi">10.1177/2055207617740315</pub-id><pub-id pub-id-type="pmid">29942620</pub-id><pub-id pub-id-type="pmcid">PMC6001198</pub-id></mixed-citation></ref><ref id="zoi250840r12"><label>12</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>McCool</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dobson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Whittaker</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Paton</surname><given-names>C</given-names></string-name></person-group>. <article-title>Mobile health (mHealth) in low- and middle-income countries</article-title>. <source>Annu Rev Public Health</source>. <year>2022</year>;<volume>43</volume>:<fpage>525</fpage>-<lpage>539</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-publhealth-052620-093850</pub-id><pub-id pub-id-type="pmid">34648368</pub-id></mixed-citation></ref><ref id="zoi250840r13"><label>13</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Piette</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>List</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rana</surname><given-names>GK</given-names></string-name>, <string-name name-style="western"><surname>Townsend</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Striplin</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Heisler</surname><given-names>M</given-names></string-name></person-group>. <article-title>Mobile health devices as tools for worldwide cardiovascular risk reduction and disease management</article-title>. <source>Circulation</source>. <year>2015</year>;<volume>132</volume>(<issue>21</issue>):<fpage>2012</fpage>-<lpage>2027</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.008723</pub-id><pub-id pub-id-type="pmid">26596977</pub-id><pub-id pub-id-type="pmcid">PMC5234768</pub-id></mixed-citation></ref><ref id="zoi250840r14"><label>14</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Arora</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Peters</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Burner</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lam</surname><given-names>CN</given-names></string-name>, <string-name name-style="western"><surname>Menchine</surname><given-names>M</given-names></string-name></person-group>. <article-title>Trial to examine text message-based mHealth in emergency department patients with diabetes (TExT-MED): a randomized controlled trial</article-title>. <source>Ann Emerg Med</source>. <year>2014</year>;<volume>63</volume>(<issue>6</issue>):<fpage>745</fpage>-<lpage>54.e6</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.annemergmed.2013.10.012</pub-id><pub-id pub-id-type="pmid">24225332</pub-id></mixed-citation></ref><ref id="zoi250840r15"><label>15</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Chow</surname><given-names>CK</given-names></string-name>, <string-name name-style="western"><surname>Redfern</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hillis</surname><given-names>GS</given-names></string-name>, <etal/></person-group>. <article-title>Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease: a randomized clinical trial</article-title>. <source>JAMA</source>. <year>2015</year>;<volume>314</volume>(<issue>12</issue>):<fpage>1255</fpage>-<lpage>1263</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2015.10945</pub-id><pub-id pub-id-type="pmid">26393848</pub-id></mixed-citation></ref><ref id="zoi250840r16"><label>16</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Dobson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Whittaker</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Effectiveness of text message based, diabetes self management support programme (SMS4BG): two arm, parallel randomised controlled trial</article-title>. <source>BMJ</source>. <year>2018</year>;<volume>361</volume>:<fpage>k1959</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.k1959</pub-id><pub-id pub-id-type="pmid">29773539</pub-id><pub-id pub-id-type="pmcid">PMC5957049</pub-id></mixed-citation></ref><ref id="zoi250840r17"><label>17</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Fortmann</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Gallo</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Garcia</surname><given-names>MI</given-names></string-name>, <etal/></person-group>. <article-title>Dulce digital: an mHealth SMS-based intervention improves glycemic control in Hispanics with type 2 diabetes</article-title>. <source>Diabetes Care</source>. <year>2017</year>;<volume>40</volume>(<issue>10</issue>):<fpage>1349</fpage>-<lpage>1355</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc17-0230</pub-id><pub-id pub-id-type="pmid">28600309</pub-id><pub-id pub-id-type="pmcid">PMC5606313</pub-id></mixed-citation></ref><ref id="zoi250840r18"><label>18</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Huo</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Krumholz</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Effects of Mobile text messaging on glycemic control in patients with coronary heart disease and diabetes mellitus: a randomized clinical trial</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2019</year>;<volume>12</volume>(<issue>9</issue>):<elocation-id>e005805</elocation-id>. doi:<pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.119.005805</pub-id><pub-id pub-id-type="pmid">31474119</pub-id></mixed-citation></ref><ref id="zoi250840r19"><label>19</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Nelson</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Greevy</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Spieker</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Effects of a tailored text messaging intervention among diverse adults with type 2 diabetes: evidence from the 15-month REACH randomized controlled trial</article-title>. <source>Diabetes Care</source>. <year>2021</year>;<volume>44</volume>(<issue>1</issue>):<fpage>26</fpage>-<lpage>34</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc20-0961</pub-id><pub-id pub-id-type="pmid">33154039</pub-id><pub-id pub-id-type="pmcid">PMC7783936</pub-id></mixed-citation></ref><ref id="zoi250840r20"><label>20</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>van den Berg</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Grabe</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Baumeister</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Freyberger</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Hoffmann</surname><given-names>W</given-names></string-name></person-group>. <article-title>A telephone- and text message-based telemedicine concept for patients with mental health disorders: results of a randomized controlled trial</article-title>. <source>Psychother Psychosom</source>. <year>2015</year>;<volume>84</volume>(<issue>2</issue>):<fpage>82</fpage>-<lpage>89</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000369468</pub-id><pub-id pub-id-type="pmid">25721861</pub-id></mixed-citation></ref><ref id="zoi250840r21"><label>21</label><mixed-citation publication-type="journal"><person-group><collab>World Medical Association</collab></person-group>. <article-title>World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects</article-title>. <source>JAMA</source>. <year>2013</year>;<volume>310</volume>(<issue>20</issue>):<fpage>2191</fpage>-<lpage>2194</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2013.281053</pub-id><pub-id pub-id-type="pmid">24141714</pub-id></mixed-citation></ref><ref id="zoi250840r22"><label>22</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Weng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>W</given-names></string-name>, <etal/>; <collab>Chinese Diabetes Society</collab></person-group>. <article-title>Standards of care for type 2 diabetes in China</article-title>. <source>Diabetes Metab Res Rev</source>. <year>2016</year>;<volume>32</volume>(<issue>5</issue>):<fpage>442</fpage>-<lpage>458</lpage>. doi:<pub-id pub-id-type="doi">10.1002/dmrr.2827</pub-id><pub-id pub-id-type="pmid">27464264</pub-id></mixed-citation></ref><ref id="zoi250840r23"><label>23</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Association</surname><given-names>AD</given-names></string-name>; <collab>American Diabetes Association</collab></person-group>. <article-title>4. Lifestyle management: standards of medical care in diabetes-2018.</article-title><source>Diabetes Care</source>. <year>2018</year>;<volume>41</volume>(<issue>suppl 1</issue>):<fpage>S38</fpage>-<lpage>S50</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc18-S004</pub-id><pub-id pub-id-type="pmid">29222375</pub-id></mixed-citation></ref><ref id="zoi250840r24"><label>24</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Craig</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Marshall</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Sj&#246;str&#246;m</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>International physical activity questionnaire: 12-country reliability and validity</article-title>. <source>Med Sci Sports Exerc</source>. <year>2003</year>;<volume>35</volume>(<issue>8</issue>):<fpage>1381</fpage>-<lpage>1395</lpage>. doi:<pub-id pub-id-type="doi">10.1249/01.MSS.0000078924.61453.FB</pub-id><pub-id pub-id-type="pmid">12900694</pub-id></mixed-citation></ref><ref id="zoi250840r25"><label>25</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Huo</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Spatz</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>Design and rationale of the Cardiovascular Health and Text Messaging (CHAT) Study and the CHAT-Diabetes Mellitus (CHAT-DM) Study: two randomised controlled trials of text messaging to improve secondary prevention for coronary heart disease and diabetes</article-title>. <source>BMJ Open</source>. <year>2017</year>;<volume>7</volume>(<issue>12</issue>):<elocation-id>e018302</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmjopen-2017-018302</pub-id><pub-id pub-id-type="pmid">29273661</pub-id><pub-id pub-id-type="pmcid">PMC5778311</pub-id></mixed-citation></ref><ref id="zoi250840r26"><label>26</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Roy</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ryan</surname><given-names>LM</given-names></string-name></person-group>. <article-title>Scaled marginal models for multiple continuous outcomes</article-title>. <source>Biostatistics</source>. <year>2003</year>;<volume>4</volume>(<issue>3</issue>):<fpage>371</fpage>-<lpage>383</lpage>. doi:<pub-id pub-id-type="doi">10.1093/biostatistics/4.3.371</pub-id><pub-id pub-id-type="pmid">12925505</pub-id></mixed-citation></ref><ref id="zoi250840r27"><label>27</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Fischer</surname><given-names>HH</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname><given-names>IP</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname><given-names>RI</given-names></string-name>, <etal/></person-group>. <article-title>Text message support for weight loss in patients with prediabetes: a randomized clinical trial</article-title>. <source>Diabetes Care</source>. <year>2016</year>;<volume>39</volume>(<issue>8</issue>):<fpage>1364</fpage>-<lpage>1370</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc15-2137</pub-id><pub-id pub-id-type="pmid">26861922</pub-id></mixed-citation></ref><ref id="zoi250840r28"><label>28</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Zheng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Spatz</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Effect of text messaging on risk factor management in patients with coronary heart disease: the CHAT randomized clinical trial</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2019</year>;<volume>12</volume>(<issue>4</issue>):<elocation-id>e005616</elocation-id>. doi:<pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.119.005616</pub-id><pub-id pub-id-type="pmid">30998400</pub-id></mixed-citation></ref><ref id="zoi250840r29"><label>29</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Dobson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Whittaker</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Long-term follow-up of a randomized controlled trial of a text-message diabetes self-management support programme, SMS4BG</article-title>. <source>Diabet Med</source>. <year>2020</year>;<volume>37</volume>(<issue>2</issue>):<fpage>311</fpage>-<lpage>318</lpage>. doi:<pub-id pub-id-type="doi">10.1111/dme.14182</pub-id><pub-id pub-id-type="pmid">31722130</pub-id><pub-id pub-id-type="pmcid">PMC7004024</pub-id></mixed-citation></ref><ref id="zoi250840r30"><label>30</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Alsahli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Abd-Alrazaq</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Househ</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Konstantinidis</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Blake</surname><given-names>H</given-names></string-name></person-group>. <article-title>The effectiveness of mobile phone messaging-based interventions to promote physical activity in type 2 diabetes mellitus: systematic review and meta-analysis</article-title>. <source>J Med Internet Res</source>. <year>2022</year>;<volume>24</volume>(<issue>3</issue>):<elocation-id>e29663</elocation-id>. doi:<pub-id pub-id-type="doi">10.2196/29663</pub-id><pub-id pub-id-type="pmid">35258463</pub-id><pub-id pub-id-type="pmcid">PMC8941442</pub-id></mixed-citation></ref><ref id="zoi250840r31"><label>31</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Sahin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Courtney</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Naylor</surname><given-names>PJ, E</given-names></string-name><string-name name-style="western"><surname>Rhodes</surname><given-names>R</given-names></string-name></person-group>. <article-title>Tailored mobile text messaging interventions targeting type 2 diabetes self-management: a systematic review and a meta-analysis</article-title>. <source>Digital Health</source>. <year>2019</year>;5. doi:<pub-id pub-id-type="doi">10.1177/2055207619845279</pub-id><pub-id pub-id-type="pmcid">PMC6481002</pub-id><pub-id pub-id-type="pmid">31041110</pub-id></mixed-citation></ref><ref id="zoi250840r32"><label>32</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Haider</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sudini</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chow</surname><given-names>CK</given-names></string-name>, <string-name name-style="western"><surname>Cheung</surname><given-names>NW</given-names></string-name></person-group>. <article-title>Mobile phone text messaging in improving glycaemic control for patients with type 2 diabetes mellitus: A systematic review and meta-analysis</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2019</year>;<volume>150</volume>:<fpage>27</fpage>-<lpage>37</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.diabres.2019.02.022</pub-id><pub-id pub-id-type="pmid">30822496</pub-id></mixed-citation></ref><ref id="zoi250840r33"><label>33</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hou</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Carter</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hewitt</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Francisa</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Mayor</surname><given-names>S</given-names></string-name></person-group>. <article-title>Do mobile phone applications improve glycemic control (HbA1c) in the self-management of diabetes? a systematic review, meta-analysis, and grade of 14 randomized trials</article-title>. <source>Diabetes Care</source>. <year>2016</year>;<volume>39</volume>(<issue>11</issue>):<fpage>2089</fpage>-<lpage>2095</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc16-0346</pub-id><pub-id pub-id-type="pmid">27926892</pub-id></mixed-citation></ref><ref id="zoi250840r34"><label>34</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Emdin</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Rahimi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Neal</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Callender</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Perkovic</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>A</given-names></string-name></person-group>. <article-title>Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis</article-title>. <source>JAMA</source>;<year>2015</year>;<volume>313</volume>(<issue>6</issue>):<fpage>603</fpage>-<lpage>615</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2014.18574</pub-id><pub-id pub-id-type="pmid">25668264</pub-id></mixed-citation></ref><ref id="zoi250840r35"><label>35</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Stratton</surname><given-names>IM</given-names></string-name>, <string-name name-style="western"><surname>Adler</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Neil</surname><given-names>HA</given-names></string-name>, <etal/></person-group>. <article-title>Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study</article-title>. <source>BMJ</source>. <year>2000</year>; <volume>321</volume>(<issue>7258</issue>): <fpage>405</fpage>-<lpage>412</lpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.321.7258.405</pub-id><pub-id pub-id-type="pmid">10938048</pub-id><pub-id pub-id-type="pmcid">PMC27454</pub-id></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-ZOI250840-1"><supplementary-material id="note-ZOI250840-1-s" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1.</label><caption><p>
Trial Protocol
</p></caption><media xlink:href="jamanetwopen-e2529762-s001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 2.</label><caption><p><bold>eTable 1.</bold> Primary and Secondary End Point Analyses at 6 and 12 Months of Follow-Up Using Multiple Imputation for Missing Data</p><p><bold>eTable 2.</bold> Changes in the HbA1c Levels by Subgroups at 12 Months of Follow-Up</p><p><bold>eTable 3.</bold> Changes in the LDL-C levels by Subgroups at 12 Months of Follow-Up</p><p><bold>eTable 4.</bold> Changes in the SBP Levels by Subgroups at 12 Months of Follow-Up</p><p><bold>eTable 5.</bold> Changes in the Medication Adherence, Dietary Intake and Physical Activity During the 12-Month Follow-Up</p><p><bold>eTable 6.</bold> Changes in the Proportions of Medication Recipient at 6 and 12 Months of Follow-Up</p><p><bold>eFigure 1.</bold> Absolute Waist Circumference, Weight, BMI and Diastolic BP Levels According to Randomization Group</p><p><bold>eFigure 2.</bold> Absolute Fasting Glucose, TC, TG and HDL-C Levels According to Randomization Group</p></caption><media xlink:href="jamanetwopen-e2529762-s002.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 3.</label><caption><p>
Data Sharing Statement
</p></caption><media xlink:href="jamanetwopen-e2529762-s003.pdf" position="float" orientation="portrait"/></supplementary-material></notes></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>